Last mentioned: Mar 25, 2026
Phase III Initiation
First patient dosed in the pivotal Phase III clinical trial for endometriosis.
Phase II Completion
Positive results from Phase II studies demonstrate pain reduction and safety.
Licensing Agreement
Hope Medicine acquires global rights for HMI-115 from Bayer.
Hope Medicine has officially initiated its Phase III clinical trial for endometriosis, dosing the first patient with HMI-115. This milestone marks a significant advancement in the development of a first-in-class prolactin receptor antagonist designed to address the high unmet need in women's health.
Hope Medicine has officially initiated its global Phase III clinical trial for HMI-115, a first-in-class monoclonal antibody targeting the prolactin receptor for endometriosis. The dosing of the first patient marks a critical transition toward non-hormonal therapeutic options for a condition affecting nearly 10% of women globally.